Tag: ado-trastuzumab emtansine
Ado-trastuzumab emtansine Approved for the Treatment of Early Breast Cancer
In early May 2019, the United States Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (Kadcyla®, Genentech/Roche; T-DM1) for the adjuvant treatment of patients...
New Hydrophilic Auristatin Payload Improves Antibody-Drug Conjugate Efficacy and Biocompatibility
Antibody-drug conjugates or ADCs, which link an antibody to a potent, small-molecule, cytotoxic, cell-killing, chemotherapeutic agent, use the target-specificity of monoclonal antibodies or antibody...
Antibody-Drug Conjugates at the 59th American Society of Hematology Annual...
This year, in Atlanta, the South's largest and most vibrant city, the 59th annual meeting and exposition of the American Society of Hematology, to...
YProtech: Specialists in High Value Chemistries, from Early Research and Lead...
Established in 2011 YProtech is a leading Chemistry Services Contract Research Organization specializing in high value chemistry services.
The company offers niche chemistry based services...
Antibody-drug Conjugates: Technologies and Global Markets
Less than 3 decades old, antibody-drug conjugate or ADC-technology is a relatively new. Due to many technological advances, recognition of appropriate target antigens, success...
Market Growth, Demand, Trends and Share of Antibody-drug Conjugates (2017 –...
A report published by Persistence Market Research (PMR), a U.S.-based full-service market intelligence firm specializing in syndicated research, shows that the global market for...
PEGS Boston 2017: Catalent Biologics Advances Antibody-Drug Conjugate Development
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that...
Bridging HER2 and Prolactin Receptor Improves Efficacy of an HER2 ADCs.
Authors: Andreev J, Thambi N, Perez Bay AE, Delfino FJ, Martin JH, Kelly MP, Kirshner JR, Rafique A, Kunz A, Nittoli T, MacDonald D,...
Improving Outcomes in the Treatment of Breast Cancer (Video)
Over the last 25 years, there has been an explosion of new and vitally important, anticancer drugs.
The development of these promising new therapeutic agents...
A Call to Action: Submit Your Expertise
Valuable lessons learned from both approved antibody-drug conjugates (brentuximab vedotin /Adcetris®; Seattle Genetics approved in 2011 and ado-trastuzumab emtansine or T-DM-1/Kadcyla® approved in 2013)...
